There are currently 1094 clinical trials in Rochester, Minnesota looking for participants to engage in research studies. Trials are conducted at various facilities, including Mayo Clinic, Mayo Clinic in Rochester, Mayo Clinic - Rochester and Mayo Clinic Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Improving Cardiac Rehabilitation Outcomes Through Mobile Case Management (iCARE)
NCT04938661
Recruiting
The purpose of this research is to find out if doing cardiac rehab at home, or a mix of cardiac rehab at home and in the clinic, is as effective as coming in to the clinic for cardiac rehab.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
09/04/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Acute Myocardial Infarction, Acute Coronary Syndrome, Stable Angina Pectoris, Percutaneous Coronary Intervention, Heart Failure
Register for Updates
North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)
NCT01694940
Recruiting
The North American Mitochondrial Disease Consortium (NAMDC) maintains a patient contact registry and tissue biorepository for patients with mitochondrial disorders.
Gender:
ALL
Ages:
All
Trial Updated:
09/03/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Mitochondrial Disorders, Mitochondrial Genetic Disorders, Mitochondrial Diseases, Disorder of Mitochondrial Respiratory Chain Complexes, Deletion and Duplication of Mitochondrial DNA
Register for Updates
Study of Disrupted Sleep in Somali Americans
NCT05411029
Recruiting
The aims of this study are to determine the types and severity of previously undiagnosed sleep deficiencies in otherwise healthy Somali Americans, apply a research framework to define psychosocial, behavioral, environmental, and biological mechanisms mediating sleep deficiencies in Somali Americans, and examine the relationship between sleep deficiencies and increased blood pressure in Somali Americans.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
09/03/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Hypertension, Sleep Disorder, Healthy
Register for Updates
Nonlinear Elasticity Mapping of Breast Masses
NCT04863443
Recruiting
This proposed technique, called "Nonlinear Elasticity Mapping (NEM)", is an innovative approach to estimate (i.e., linear and nonlinear) elasticity to provide complementary and relevant information for identification and characterization of breast masses. The proposed technique includes imaging the (nonlinear) elasticity parameter in a quantitative manner and measuring two new and relevant parameters. These parameters, together with linear elasticity, are used to differentiate breast masses. Th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/30/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Breast Cancer
Register for Updates
The REgistry of Very Early Estrogen and AnovuLation
NCT06583408
Recruiting
The purpose of this study is to to build a registry of women with early estrogen loss due to Functional Hypothalamic Amenorrhea (FHA) to understand the prevalence, racial and ethnic diversity of this condition.
Gender:
FEMALE
Ages:
Between 18 years and 40 years
Trial Updated:
08/30/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Hypothalamic Amenorrhea, Functional, Hypothalamic Amenorrhea, Functional Hypogonadotropic Hypogonadism
Register for Updates
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
NCT04756726
Recruiting
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of oral cemsidomide (also known as CFT7455) administered at different dosages in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). Cemsidomide may be administered as a single agent and, in MM only, in combination with oral dexamethasone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/27/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin's
Register for Updates
From Opinion to Evidence: Multi-site Evaluation of Custom Dynamic Orthosis Best Practices
NCT06352788
Recruiting
This study is designed to support evidence-based practice and optimal care by evaluating how different configurations of two types of carbon fiber custom dynamic orthoses (CDOs) influences outcomes following traumatic lower extremity injury.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/26/2024
Locations: Mayo Clinic - Motion Analysis Lab, Rochester, Minnesota
Conditions: Foot Injury
Register for Updates
Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)
NCT04543253
Recruiting
Cushing syndrome (CS) is an endocrine disorder caused by chronic exposure to glucocorticoid (GC) excess. Endogenous CS has an estimated incidence of 0.2 to 5.0 cases per million per year and prevalence of 39 to 79 cases per million in various populations. CS usually affects young women, with a median age at diagnosis of 41.4 with a female-to-male ratio of 3:1. Following a curative surgery for CS, patients develop adrenal insufficiency and require GC replacement postoperatively until the hypothal... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/23/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Cushing Syndrome
Register for Updates
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
NCT04071457
Recruiting
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Ste... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/21/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Multiple Myeloma
Register for Updates
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
NCT05732103
Recruiting
The goal of this phase 1/2 multicenter, open-label, singe arm dose escalation and expansion study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic profile of CTX-712 in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and higher risk myelodysplastic syndromes (HR-MDS). The phase 1 part of the study consists of sequential standard 3 + 3 dose escalation, where patients will receive ascending doses of CTX-712 to determine the recommended phase 2 dose (... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2024
Locations: Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Register for Updates
ALgorithms Adapted From Remote Monitoring
NCT05782140
Recruiting
Through the aid of remote monitoring and early symptom detection, a patient's response to stress and normalization to their individual baseline can better contribute towards algorithms which are predictive of clinical decline.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Surgery
Register for Updates
Voice Analysis for Monitoring Patients With Heart Failure
NCT06566911
Recruiting
This observational study involves ADHF patients at two sites in the United States and Germany. After informed consent and screening assessments, participants will perform daily voice recordings during their hospital stay, from admission until discharge. Alongside voice data, additional clinical information such as left ventricular ejection fraction, NTpro-BNP levels, and ECG-data will be collected for comprehensive analysis. The study's goal is to identify voice-based indicators of heart failure... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/19/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Heart Failure
Register for Updates